AXXE | Axxess Pharma, Inc. & Extended Watchlist

Axxess Pharma, Inc. AXXE
We’re touching base with AXXE again this morning, as the company has made some exciting announcements over the past couple of days including the acquisition of assets previously belonging to Revive Bioscience Inc., a Canadian OTC healthcare company, a move that widens AXXE’s catalog of pharma products significantly. Even more exciting is the fact that Revive held the rights to several branded OTC products endorsed by professional athletes in many major American sports including the NFL, NHL, and more.

Additionally, in a PR from yesterday we learned that AXXE has also made an addition to an already strong management team, with the appointment of Robert Tallack, who will serve as VP of Sales and Marketing. You can read more in depth about both developments by clicking through the press links below, but first, we’re going to take a look at how the AXXE chart is faring via the following video:

Be sure to check out the Exclusive Interview our sister site, Stock Traders Talk, conducted with AXXE President Dr. Daniel Bagi last week:
AXXE Interview

You can also take a look at our initial report on the company:
AXXE Report



Extended Watchlist:
FREE, DRYS, GOGO, RAD

AXXE | Axxess Pharma, Inc. | Today’s Focus


Axxess Pharma, Inc. AXXE

We’re putting AXXE on our radars this morning, a new play with a chart that appears to have potential. As always when we focus on a new company, we’d first like to take a few minutes to familiarize ourselves with the business behind the stock.

Axxess Pharma has an expansive line which includes twenty-three prescription and non-prescription strength products, which are used in the treatment of a variety of ailments, including but not limited to: iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, and joint pain.

The company has been taking steps to make these products available to the public at an affordable price.

AXXE recently signed an agreement with a Mexican pharma company that will facilitate the distribution of its Soropon product to the Mexican population, which, according to President and CEO Dr. Daniel Bagi, is ” three times that of Canada’s and has a higher birth rate than Canada. AXXE is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014.”

That and more was covered yesterday when we conducted an Exclusive Interview with Dr. Bagi via our sister site, Stock Traders Talk. It covered a lot of important things, so be sure to take a few minutes to check that out on StockTradersTalk.com when it becomes available this afternoon!

AXXE EXCLUSIVE INTERVIEW
Available after 1:00PM today, only on Stock Traders Talk!


Now to go over the AXXE chart, for which we’ve provided the following video presentation:


Axxess has been awfully busy of late, making several news announcements already this month. Between its active approach to shareholder outreach via press release, as well as the CEO making the time to take part in our interview, we can see that this company places a high emphasis on transparency and visibility. To that end, if you read ahead to the PRs, we find that AXXE is actually making preparations for an uplisting to the OTC Bulletin Board.

SEPTEMBER PRESS RELEASES:

09.11.13: Axxess Pharma Inc. Initiates Next Step Towards Bulletin Board (OTCBB) Listing

09.09.13: AXXESS Pharma Inc. Signs Agreement With Top Mexican Pharmaceutical Company

09.04.13: Axxess Pharma Inc. Announces US Board Certified Cardiologist, Dr. Fred Maese as Senior Consultant

09.02.13: Axxess Pharma Inc. Announces MOU to Acquire Leading Canadian OTC Healthcare Company


More Info is available at:
www.axxesspharmainc.com